Full Length Research Paper
References
|
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990). Basic Local Alignment Search Tool. Journal of Molecular Biology 215:403-10. |
|
|
Ashley Elizabeth A, Phyo PA (2018). Drugs in Development for Malaria. Drugs 78(9):861-879. |
|
|
Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P(2006). Targeting of Hematin by the Antimalarial Pyronaridine.Antimicrobial Agents and Chemotherapy 50(6):2197-2200. |
|
|
Chang C, Lin-Hua T, Jantanavivat C (1992). Studies on a New Antimalarial Compound: Pyronaridine. Transactions of the Royal Society of Tropical Medicine and Hygiene 86(1):7-10. |
|
|
Croft SL, Duparc S, Arbe-barnes SJ, Carl Craft J, Shin C, Fleckenstein L, Borghini-fuhrer I, Rim H (2012). Review of Pyronaridine Anti-Malarial Properties and Product Characteristics. Malaria Journal 11(4):270. |
|
|
Dipanjan B, Shivaprakash G, Balaji O (2017). Triple Combination Therapy and Drug Cycling-Tangential Strategies for Countering Artemisinin Resistance. Current Infectious Disease Reports 19(7):1-7. |
|
|
Dorn A, Rani SV, Matile H, Jaquet C, Vennerstrom JL, Ridley RG (1998). An Assessment of Drug-Haematin Binding as a Mechanism for Inhibition of Haematin Polymerisation by Quinoline Antimalarials. Biochemical Pharmacology 55(97):727-736. |
|
|
Duraisingh MT, Cowman AF (2005). Contribution of the Pfmdr1 Gene to Antimalarial Drug-Resistance. Acta Tropica 94:181-190. |
|
|
Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S (2004). Antimalarial Drug Discovery: Efficacy Models for Compound Screening. Nature Reviews Drug Discovery 3(6):509-520. |
|
|
Gupta S, Thapar MM, Mariga ST, Wernsdorfer WH,Björkman A (2002). Plasmodium falciparum: In Vitro Interactions of Artemisinin with Amodiaquine, Pyronaridine, and Chloroquine. Experimental Parasitology 100(1):28-35. |
|
|
Hanboonkunupakarn B, White NJ (2015). The Threat of Antimalarial Drug Resistance. Tropical Diseases, Travel Medicine and Vaccines 2(1):1-5. |
|
|
Hastings IM, Hodel EM (2014). Pharmacological Considerations in the Design of Anti-Malarial Drug Combination Therapies - Is Matching Half-Lives Enough? Malaria Journal 13 (1):1-15. |
|
|
Henrich PP, Brien CO, Sáenz FE, Cremers S, Kyle DE, Fidock DA (2014). Evidence for Pyronaridine as a Highly Effective Partner Drug for Treatment of Artemisinin-Resistant Malaria in a Rodent Model. Antimicrobial Agents and Chemotherapy 58(1):183-95. |
|
|
Hien TT, Thuy-Nhien NT, Phu HN, Boni MF, Thanh NV, Nha-Ca NT, Thai L (2012). In Vivo Susceptibility of Plasmodium falciparum to Artesunate in Binh Phuoc Province, Vietnam. Malaria Journal 11:1-11. |
|
|
Janse C, Ramesar J, Waters A (2004). Plasmodium Berghei: General Parasitological Methods.Leiden University Medical Center, The Netherlands pp. 26-27. |
|
|
Kiboi, DM, Irungu B, Orwa J, Kamau L, Ochola-oyier LI, Ngángá J, Nzila A (2014). Experimental Parasitology Piperaquine and Lumefantrine Resistance in Plasmodium berghei ANKA Associated with Increased Expression of Ca 2 + / H + Antiporter and Glutathione Associated Enzymes. Experimental Parasitology 147:23-32. |
|
|
Kimani SK, Ng JK, Kariuki DW, Kinyua J, Kimani FT, Kiboi DM (2014). Plasmodium berghei ANKA : Selection of Pyronaridine Resistance in Mouse Model. African Journal of Biochemistry Research 8(6):111-17. |
|
|
Kumar S, Stecher G, Li M, Knyaz C, Tamura K (2018). MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Molecular Biology and Evolution 35(6):1547-1549. |
|
|
Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye M, Lindegardh N (2013). Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar. PLoS ONE 8(3). |
|
|
Li GD, Liu SQ, Ye XY, Qu FY (1995). Detection of 54-KDa Protein Overexpressed by Chloroquine-Resistant Plasmodium berghei ANKA Strain in Pyronaridine-Resistant P. berghei ANKA Strain] (in Chinese). Pharmacologica Sinica 16(1):17-20. |
|
|
Li Q, Hickman M (2015). The Impact of Pharmacokinetic Mismatched Antimalarial Drug Combinations on the Emergence and Spread of Drug Resistant Parasites. Basic Pharmacokinetic Concepts and Some Clinical Applications 1:1-32. |
|
|
Livak KJ, Schmittgen TD(2001). Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔCT Method. Methods 25(4):402-408. |
|
|
Menard D, Dondorp A (2017). Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb Perspect Medicine. |
|
|
Merkli B, Richle RW (1980). Studies on the Resistance to Single and Combined Antimalarials in the Plasmodium berghei Mouse Model. Acta Tropica 37:228-231. |
|
|
Mishra M, Mishra VK, Kashaw V, Iyer AK, Kashaw SK (2017). Comprehensive Review on Various Strategies for Antimalarial Drug Discovery. European Journal of Medicinal Chemistry 125:1300-1320. |
|
|
Ouji M, Augereau JM, Paloque L, Benoit-Vical F (2018). Plasmodium falciparum Resistance to Artemisinin-Based Combination Therapies: A Sword of Damocles in the Path toward Malaria Elimination. Parasite 25:24-30. |
|
|
Park SH, Pradeep K (2010). Absorption, Distribution, Excretion, and Pharmacokinetics of C 14 -Pyronaridine Tetraphosphate in Male and Female Sprague-Dawley Rats. Journal of Biomedicine and Biotechnology 59:1-9. |
|
|
Peters W, Robinson BL (1992). The Chemotherapy of Rodent Malaria. XLVII. Studies on Pyronaridine and Other Mannich Base Antimalarials. Annals of Tropical Medicine and Parasitology 86(5):455-465. |
|
|
Pradines B, Briolant S, Henry M, Oeuvray C, Baret E, Amalvict R, Didillon E, Rogier C (2010). Absence of Association between Pyronaridine in Vitro Responses and Polymorphisms in Genes Involved in Quinoline Resistance in Plasmodium falciparum. Malaria Journal 9:339. |
|
|
Qi J, Yang CZ, Wang CY, Wang SB, Yang M, Wang JH (2002). Function and Mechanism of Pyronaridine: A New Inhibitor of P-Glycoprotein-Mediated Multidrug Resistance. Acta Pharmaceutica Sinica 23:544-550. |
|
|
Qi J, Wang S, Liu G, Peng H, Wang J, Zhu Z, Yang C (2004). Pyronaridine, a Novel Modulator of P-Glycoprotein-Mediated Multidrug Resistance in Tumor Cells in Vitro and in Vivo. Biochemical and Biophysical Research Communications 319(4):1124-1131. |
|
|
Ramharter M, Kurth F, Schreier AC, Nemeth J, Von Glasenapp I, Schlie M, Kammer J (2008). Fixed-Dose Pyronaridine-Artesunate Combination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. Journal of Infectious Diseases 198:911-19. |
|
|
Rathod P, Mcerlean T, Lee P (1997). Variations in Frequencies of Drug Resistance in Plasmodium falciparum. Proceedings of the National Academy of Sciences 94:9389-9393. |
|
|
Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C(2009). Failure of Artesunate-Mefloquine Combination Therapy for Uncomplicated Plasmodium falciparum Malaria in Southern. Malaria Journal 9:1-9. |
|
|
Tang Y, Ye Q, Huang H, Zheng W (2020). An Overview of Available Antimalarials: Discovery, Mode of Action and Drug Resistance Current Molecular Medicine 20(8):583-592. |
|
|
Tse EG, Korsik M, Todd MH (2019). The Past, Present and Future of Anti-Malarial Medicines. Malaria Journal 18(1):1-21. |
|
|
Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, Croft SL (2008). Anti-Malarial Efficacy of Pyronaridine and Artesunate in Combination in Vitro and in Vivo. Acta Tropica 105(3):222-228. |
|
|
World Health Organization (WHO) (2017). World malaria report 2017. |
|
|
World Health Organization (WHO) (2020). The use artesunate-pyronaridine for the treatmnt of uncomplicated malaria. |
|
|
Woodrow CJ, Krishna S (2006). Antimalarial Drugs : Recent Advances in Molecular Determinants of Resistance and Their Clinical Significance. Cell Molecular Life Science 63:1586-1596. |
|
|
Wu LJ, Rabbege JR, Nagasawa H, Jacobs G, Aikawa M (1988). Morphological Effects of Pyronaridine on Malarial Parasites. American Journal of Tropical Medicine and Hygiene 9:87-89. |
|
Copyright © 2023 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
